CLINICAL TRIALS PROFILE FOR CEDIRANIB
✉ Email this page to a colleague
Clinical Trials for Cediranib
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00107250 ↗ | AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07) | Completed | NCIC Clinical Trials Group | Phase 1 | RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, carboplatin, or capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AZD2171 together with chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of AZD2171 when given together with chemotherapy in treating patients with advanced non-small cell lung cancer (closed to enrollment as of 8/9/07), colorectal cancer, or other cancer suitable to capecitabine treatment. |
| NCT00227760 ↗ | Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery | Completed | National Cancer Institute (NCI) | Phase 2 | This phase II trial studies how well cediranib maleate works in treating patients with recurrent or metastatic kidney cancer that cannot be removed by surgery. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT00238394 ↗ | Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well AZD2171 works in treating patients with locally advanced or metastatic liver cancer. |
| NCT00243061 ↗ | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma | Completed | National Cancer Institute (NCI) | Phase 2 | This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. |
| NCT00243074 ↗ | S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery | Completed | National Cancer Institute (NCI) | Phase 2 | This phase II trial is study how well AZD2171 works in treating patients with malignant pleural mesothelioma that cannot be removed by surgery. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Cediranib
Condition Name
Clinical Trial Locations for Cediranib
Trials by Country
Clinical Trial Progress for Cediranib
Clinical Trial Phase
Clinical Trial Sponsors for Cediranib
Sponsor Name
